STUDIES RELATED TO THE POTENTIAL ANTIGENICITY OF THE BOWMAN-BIRK INHIBITOR, AN ANTICARCINOGENIC PROTEASE INHIBITOR ISOLATED FROM SOYBEANS

Citation
Pa. Maki et al., STUDIES RELATED TO THE POTENTIAL ANTIGENICITY OF THE BOWMAN-BIRK INHIBITOR, AN ANTICARCINOGENIC PROTEASE INHIBITOR ISOLATED FROM SOYBEANS, Nutrition and cancer, 22(2), 1994, pp. 185-193
Citations number
25
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Nutrition & Dietetics",Oncology
Journal title
ISSN journal
0163-5581
Volume
22
Issue
2
Year of publication
1994
Pages
185 - 193
Database
ISI
SICI code
0163-5581(1994)22:2<185:SRTTPA>2.0.ZU;2-3
Abstract
Soybeans are known to contain certain proteins that are allergenic; th erefore the anticarcinogenic Bowman-Birk protease inhibitor (BBI), an 8-kDa protein isolated from soybeans, could be capable of generating a n immune response that would contraindicate its use as a cancer chemop reventive agent. In the present investigation, the stimulation of anti body production in response to BBI was measured after the administrati on of BBI by various routes and treatment regimens. A significant anti body titer to BBI was observed when the animals were treated with BBI by intraperitoneal injection once or three times per week. In these st udies, higher antibody titers were observed at earlier time points. Wh en the animals were treated with BBI by oral gavage, little or no anti body production was observed, regardless of the treatment regimen. The doses and treatment regimens used in this study have been previously demonstrated to be effective in preventing tumor formation. The result s of this study indicate that antibody production in response to BBI a dministered orally should not present a complication to BBI treatment.